Pharma sector pushes back against a programme that mandates cheaper prices for hospitals serving the poor.
Ionis seeks a green light for Waylivra in a rare disease, but safety concerns could seriously hit sales. Meanwhile, Intra-Cellular needs a pivotal bipolar trial win for…
As Brainsway pioneers a new option in obsessive compulsive disorder, Vantage looks at how these devices have moved into new indications over the past decade.
To determine whether Medicare covers CAR-T it might soon be important to find out how patients feel.
Roche will find out by September 5 whether its shot at a first-line US lung cancer label has hit the mark.
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
The Danish company’s latest deal covers glucose-sensitive insulin, which could avoid hypoglycaemia in type 2 diabetes patients.
A looming interim analysis could make Amryt a player in epidermolysis bullosa – and boost its deal-making ambitions.
If investors have visions of Luxturna-like prices they might need to blink and look again.